These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Novel targets and approaches in advanced prostate cancer. Hadaschik BA; Sowery RD; Gleave ME Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516 [TBL] [Abstract][Full Text] [Related]
3. New drugs in prostate cancer. Armstrong AJ; Carducci MA Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849 [TBL] [Abstract][Full Text] [Related]
4. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Di Lorenzo G; De Placido S Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343 [TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Ryan CJ; Lin AM; Small EJ Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059 [TBL] [Abstract][Full Text] [Related]
11. New molecular targets in advanced prostate cancer. Dawson NA Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for advanced prostate cancer: Looking through new lenses. Vogiatzi P; Cassone M; Claudio L; Claudio PP Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279 [TBL] [Abstract][Full Text] [Related]
13. The role of systemic cytotoxic therapy for prostate cancer. Chang SS; Kibel AS BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for prostate cancer - recent progress in clinical trials. Kipp RT; McNeel DG Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921 [TBL] [Abstract][Full Text] [Related]
15. Management of the spectrum of hormone refractory prostate cancer. Clarke NW Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118 [TBL] [Abstract][Full Text] [Related]
16. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. McCarty MF Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106 [TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. Priolo C; Oh WK; Loda M IDrugs; 2009 Mar; 12(3):165-8. PubMed ID: 19333896 [TBL] [Abstract][Full Text] [Related]
18. New strategies for the medical treatment of prostate cancer. Isaacs JT BJU Int; 2005 Dec; 96 Suppl 2():35-40. PubMed ID: 16359437 [TBL] [Abstract][Full Text] [Related]
19. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920 [TBL] [Abstract][Full Text] [Related]
20. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Sava T; Basso U; Porcaro A; Cetto GL Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]